Hematologic Oncology | Ruben A Mesa, MD - a podcast by Dr Neil Love
from 2019-05-03T20:00
::
::
Myeloproliferative Neoplasms Update — Part 1: Our interview with Dr Mesa highlights the following topics and cases from his practice:
- Molecular pathogenesis of myeloproliferative neoplasms (MPNs) (00:00)
- Cytokine activation and its association with the distinct symptomatology of MPNs (3:42)
- Targeting the JAK-STAT pathway in myelofibrosis (MF) and polycythemia vera (PV) (5:19)
- Case:A 66-year-old man with symptomatic primary MF with a CALR mutation receives ruxolitinib (9:05)
- Clinical parameters to evaluate when considering treatment with ruxolitinib (11:23)
- Discussing the complexities of allogeneic transplant with patients considering this intervention (16:05)
- Clinical outcomes and complication rates for younger versus older patients undergoing transplant (16:46)
- Counseling patients regarding the efficacy and side-effect profile of ruxolitinib (20:41)
- Symptom improvement with ruxolitinib; dosing for patients with MF (24:14)
- Management of anemia associated with ruxolitinib treatment (26:27)
- Approach to dosing ruxolitinib for patients with MF and cytopenias (29:58)
- Consideration of ruxolitinib treatment holidays and therapy reinitiation for patients with increased splenomegaly (32:22)
- Treatment options for patients with MF and disease progression on ruxolitinib (36:20)
- Clonal evolution and outcomes in MF after ruxolitinib discontinuation (38:53)
- Therapeutic options for patients who experience disease progression on ruxolitinib (41:06)
- Activity, tolerability and ongoing investigation of novel JAK inhibitors pacritinib, momelotinib and fedratinib in MF (44:36)
- FDA clinical hold on fedratinib due to possible occurrences of Wernicke encephalopathy in patients on the JAKARTA-1 trial and recent lift of the hold (47:46)
- Ongoing investigation of fedratinib in MF (48:56)
- Clinical experience with pacritinib, momelotinib and fedratinib (52:46)
- Toward identifying molecular predictors of response to pacritinib, momelotinib and fedratinib (53:59)
- Case: A 64-year-old woman with ruxolitinib-refractory MF receives fedratinib on the Phase II JAKARTA-2 trial (55:51)
- Therapeutic approach to MF that progresses to acute myeloid leukemia (59:26)
- Investigation of the novel Bcl-2 inhibitor navitoclax in combination with ruxolitinib for patients with MF (1:2:42)
- Clinical manifestations and treatment of PV (1:3:12)
- Case: A 56-year-old woman with high-risk PV and an inadequate response to hydroxyurea receives ruxolitinib (1:5:53)
- Risk stratification and treatment for patients with essential thrombocythemia (ET) (1:8:26)
Further episodes of Research To Practice | Oncology Videos
Further podcasts by Dr Neil Love
Website of Dr Neil Love